Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Experimental STI prophylaxis in PrEP users produces big drops in syphilis and chlamydia infections but not in gonorrhoea

Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men (MSM) taking part in the Ipergay HIV pre-exposure prophylaxis (PrEP)

Published
15 February 2017
By
Gus Cairns
Treatment-as-prevention study sees substantial levels of transmitted drug resistance in participants, but no impact on treatment

A study of the prevalence of transmitted drug resistance in participants in the ANRS 12249 trial of treatment as prevention, which reported its main results at the International

Published
15 February 2017
By
Gus Cairns
Case Report of PrEP Failure: What Can We Learn From It?

The New England Journal of Medicine has published the first well-documented case of HIV pre-exposure prophylaxis (PrEP) failure despite good medication adherence. We heard lots of this information at CROI last year, and again I'm impressed at the extraordinary degree of virologic investigation done on a case from clinical practice.

Published
08 February 2017
From
The Body Pro
The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance

Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.

Published
04 January 2017
From
Huffington Post
Virologic failure detected in a quarter of ART-treated children in Tanzania

A quarter of children and adolescents in Tanzania taking antiretroviral therapy (ART) have major resistance to one or more anti-HIV drug, investigators report in AIDS. In 86%

Published
28 December 2016
By
Michael Carter
High prevalence of resistance to zidovudine among people in sub-Saharan Africa experiencing virological failure with tenofovir-containing ART

A significant proportion of people with virological failure after treatment with tenofovir-containing antiretroviral therapy (ART) have resistance to thymidine analogues (stavudine and zidovudine), and in many cases other

Published
15 December 2016
By
Michael Carter
Rings, films or inserts? Researchers need to develop prevention products that make sense in women’s lives

“We need to think outside of the box,” Sharon Hillier of the Microbicide Trials Network told the HIV Research for Prevention (HIVR4P 2016) conference in Chicago

Published
21 October 2016
By
Roger Pebody
Second case report of PrEP failure due to drug-resistant virus

A PrEP user in New York City has become HIV positive with virus that is resistant to Truvada and other antiretroviral drugs, the HIV Research for Prevention

Published
18 October 2016
By
Roger Pebody
Spanish study gives reassurance: small HIV blips do not predict treatment failure

A very low viral load (20-49 copies/ml) during HIV therapy does not increase the risk of the subsequent virological failure of treatment (viral load above 200 copies/ml), according

Published
21 September 2016
By
Michael Carter
Four day a week ART: sub-optimal drug levels but few virological failures

A poster at IAS 2016 reported on the effectiveness of a strategy in France to use reduced dose maintenance therapy. This involved only taking ART for four rather than seven days a week.

Published
20 September 2016
From
HIV i-Base
← First12345...34Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.